ELYM: חוב כולל להון Eliem

This chart illustrating the total debt-to-equity ratio for Eliem Therapeutics (ELYM) is fixed at 0.00, highlighting the firm's reliance on external financing and clinical trial results due to a lack of revenue. Eliem Therapeutics (ELYM) develops small molecules to combat psychiatric disorders, counting on future profits secured by patent protection. The business relies on the defensive healthcare sector, which remains independent of global economic fluctuations.

The metric is calculated as the ratio of total liabilities to equity, reflecting the proportion of debt financing within the asset structure. For Eliem Therapeutics (ELYM), which attracts scientists through equity options rather than bureaucratic bonuses, this ratio determines resilience to cash flow gaps, making the tracking of changes in total debt-to-equity critical for assessing the biotech's financial autonomy.